The incidence of
melanoma is increasing faster than any other
cancer. In recent years, treatment of
melanoma and a range of other deadly
cancers has involved
immunotherapy with programmed cell death protein-1 (PD-1)/PD-1
ligand (PD-L1) checkpoint blockade which has improved survival. However, many patients do not respond or have partial response, survival benefit is in the order of months and all available PD-1/PD-L1 strategies are
antibodies requiring
intravenous infusion. There are no clinically approved small molecule pharmacologic inhibitors of the PD-1/PD-L1 system. The
benzimidazole derivative
flubendazole is a widely used
anthelmintic available over the counter in Europe. Here we demonstrate the ability of
flubendazole to inhibit human
melanoma growth and spread in mice.
Flubendazole's ability to block
tumor growth and spread was comparable to
paclitaxel. Anti-
tumor effects were observed when
flubendazole was delivered systemically not locally.
Flubendazole inhibited CD31/PECAM-1 staining indicating suppression of
tumor angiogenesis. Most surprisingly,
flubendazole inhibited PD-1 levels within the
tumors, but not PD-L1. Western blotting and flow cytometry revealed that
flubendazole inhibits PD-1 expression in cultured
melanoma cells.
Flubendazole also reduced myeloid-derived suppressor cell (MDSC) levels in
tumor tissue. Further we found that
flubendazole inhibited active (phospho-Tyr705) signal transducer and activator of transcription (STAT3), an upstream regulator of PD-1 expression. These findings uncover that
flubendazole is a novel small molecule inhibitor of not only
melanoma growth and spread but also of PD-1 and MDSC.